PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13434-13447

  Cheung, Arthur Kwok Leung ^a   Ip, Joseph Chok Yan ^a   Chu, Adrian Chi Hang ^a   Cheng, Yue ^a   Leong, Merrin Man Long ^a   Ko, Josephine Mun Yee ^a   Shuen, Wai Ho ^a,b   Lung, Hong Lok ^a   Lung, Maria Li ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Akt; EGFR; Nasopharyngeal carcinoma; PTPRG; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE G; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; PTPRG PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; ENZYME INHIBITION; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PTPRG GENE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOGENESIS; ENZYMOLOGY; GENETICS; METABOLISM; NASOPHARYNX TUMOR; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 5; SIGNAL TRANSDUCTION;

EID: 84931074310     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Dawson CW, Tramountanis G, Eliopoulos AG and Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem. 2003; 278:3694-3704.
2. Tao YG, Tan YN, Liu YP, Song X, Zeng L, Gu HH, Tang M, Li W, Yi W and Cao Y. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. Cell Signal. 2004; 16:781-790.
3. Kung CP, Meckes DG, Jr. and Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. Journal of Virology. 2011; 85:4399-4408.
4. Yip WK, Leong VC, Abdullah MA, Yusoff S and Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncology Reports. 2008; 19:319-328.
5. Hsu CH, Gao M, Chen CL, Yeh PY and Cheng AL. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology. 2005; 68:538-547.
6. Sastry SK and Elferink LA. Checks and balances: interplay of RTKs and PTPs in cancer progression. Biochem Pharmacol. 2011; 82:435-440.
7. Julien SG, Dube N, Hardy S and Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011; 11:35-49.
8. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (New York, NY. 2004; 304:1164-1166.
9. van Roon EH, de Miranda NF, van Nieuwenhuizen MP, de Meijer EJ, van Puijenbroek M, Yan PS, Huang TH, van Wezel T, Morreau H and Boer JM. Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer. Eur J Hum Genet. 2011; 19:307-312.
10. van Niekerk CC and Poels LG. Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors. Cancer Letters. 1999; 137:61-73.
11. Wang JF and Dai DQ. Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer. World J Gastroenterol. 2007; 13:5692-5698.
12. Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne M and Sorio C. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Research. 2010; 70:8896-8906.
13. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH and Tensen CP. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005; 23:3886-3896.
14. Cheung AK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, Liu ET, Shao JY, Kou CW, Chua D, Zabarovsky ER, Tsao SW, Stanbridge EJ and Lung ML. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Research. 2008; 68:8137-8145.
15. Liu S, Sugimoto Y, Sorio C, Tecchio C and Lin YC. Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7. Oncogene. 2004; 23:1256-1262.
16. Shu ST, Sugimoto Y, Liu S, Chang HL, Ye W, Wang LS, Huang YW, Yan P and Lin YC. Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res. 2010; 30:1937-1946.
17. Protopopov AI, Li J, Winberg G, Gizatullin RZ, Kashuba VI, Klein G and Zabarovsky ER. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. The Journal of Gene Medicine. 2002; 4:397-406.
18. Sorio C, Mendrola J, Lou Z, LaForgia S, Croce CM and Huebner K. Characterization of the receptor protein tyrosine phosphatase gene product PTP gamma: binding and activation by triphosphorylated nucleosides. Cancer research. 1995; 55:4855-4864.
19. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
20. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:1114-1119.
21. Suarez Pestana E, Tenev T, Gross S, Stoyanov B, Ogata M and Bohmer FD. The transmembrane protein tyrosine phosphatase RPTPsigma modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene. 1999; 18:4069-4079.
22. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M and Stacey DW. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene. 2005; 24:2599-2612.
23. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z and Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opinion on Therapeutic Targets. 2011; 15:63-74.
24. Eccles SA. The epidermal growth factor receptor/Erb-B/ HER family in normal and malignant breast biology. Int J Dev Biol. 2011; 55:685-696.
25. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK and Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther. 2003; 2:345-351.
26. Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, Hirai H, Tsushima T, Akanuma Y, Fujita T, Komuro I, Yazaki Y and Kadowaki T. Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Endocr J. 1998; 45 Suppl:S27-31.
27. Caron C, Spring K, Laramee M, Chabot C, Cloutier M, Gu H and Royal I. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells. Cell Signal. 2009; 21:943-953.
28. Deng Y, Zhang M and Riedel H. Mitogenic roles of Gab1 and Grb10 as direct cellular partners in the regulation of MAP kinase signaling. J Cell Biochem. 2008; 105:1172-1182.
29. Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT and Xiao GH. Cancer stem-like cell properties are regulated by EGFR/ AKT/beta-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. The FEBS journal. 2013; 280:2027-2041.
30. Mirenda M, Toffali L, Montresor A, Scardoni G, Sorio C and Laudanna C. Protein Tyrosine Phosphatase Receptor Type gamma Is a JAK Phosphatase and Negatively Regulates Leukocyte Integrin Activation. Journal of Immunology. 2015; 194:2168-2179.
31. Zhang P, Wu SK, Wang Y, Fan ZX, Li CR, Feng M, Xu P, Wang WD and Lang JY. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncology Letters. 2015; 9:113-118.
32. Vartanian R, Masri J, Martin J, Cloninger C, Holmes B, Artinian N, Funk A, Ruegg T and Gera J. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itchmediated JUNB degradation. Mol Cancer Res. 2011; 9:115-130.
33. Dal Col J and Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle. 2008; 7:2813-2816.
34. Zhang JX, Cai MB, Wang XP, Duan LP, Shao Q, Tong ZT, Liao DZ, Li YY, Huang MY, Zeng YX and Shao JY. Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Medical Oncology. 2013; 30:390.
35. Jiang BH and Liu LZ. AKT signaling in regulating angiogenesis. Current Cancer Drug Targets. 2008; 8:19-26.
36. Xia C, Meng Q, Cao Z, Shi X and Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. Journal of Cellular Physiology. 2006; 209:56-66.
37. Grzesiak JJ, Smith KC, Burton DW, Deftos LJ and Bouvet M. GSK3 and PKB/Akt are associated with integrinmediated regulation of PTHrP, IL-6 and IL-8 expression in FG pancreatic Cancer cells. Int J Cancer. 2005; 114:522-530.
38. Cheung AK, Ko JM, Lung HL, Chan KW, Stanbridge EJ, Zabarovsky E, Tokino T, Kashima L, Suzuki T, Kwong DL, Chua D, Tsao SW and Lung ML. Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NFkappaB- mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:8390-8395.
39. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S and Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clinical cancer research: an official journal of the American Association for Cancer Research. 1999; 5:775-782.
40. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K and Takano Y. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006; 26:3579-3583.
41. Seo Y, Baba H, Fukuda T, Takashima M and Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000; 88:2239-2245.
42. Yadav A, Kumar B, Datta J, Teknos TN and Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011; 9:1658-1667.
43. Ueda T, Shimada E and Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. Journal of Gastroenterology. 1994; 29:423-429.
44. Jiang H, Gao M, Shen Z, Luo B, Li R, Jiang X, Ding R, Ha Y, Wang Z and Jie W. Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal-epithelial reverting transition. Oncology Reports. 2014; 32:559-566.
45. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH and Lau WH. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer. 1980; 26:127-132.
46. Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, Man K, Wong AS, Ng IO and Yam JW. Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. The Journal of Pathology. 2012; 226:645-653.
47. Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao Q, Hyytiainen M, Keski-Oja J, Law S, Srivastava G, Tang J, Tsao SW, Chen H, Stanbridge EJ and Lung ML. The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. Int J Cancer. 2011; 129:565-573.
48. Lo PH, Lung HL, Cheung AK, Apte SS, Chan KW, Kwong FM, Ko JM, Cheng Y, Law S, Srivastava G, Zabarovsky ER, Tsao SW, Tang JC, Stanbridge EJ and Lung ML. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Research. 2010; 70:5567-5576.
49. Terasaka Y, Miyazaki D, Yakura K, Haruki T and Inoue Y. Induction of IL-6 in transcriptional networks in corneal epithelial cells after herpes simplex virus type 1 infection. Invest Ophthalmol Vis Sci. 2010; 51:2441-2449.
50. Cheung AK, Ip JC, Lung HL, Wu JZ, Tsao SW and Lung ML. Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma. Mol Cancer Ther. 2013; 12:1393-1401.
51. Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, Kwong DL, Lee AW, Zabarovsky ER, Stanbridge EJ, Lung HL and Lung ML. Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. Oncogene. 2012; 31:3709-3720.